Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bio-Gene Technologies Starts China Trial of CAR-T for Leukemia

publication date: May 7, 2024

Guangzhou Bio-gene Technologies has started a China Phase I trial for an autologous CAR-T cell therapy that targets CLL-1, a member of the C-type lectin-like receptor family, in patients with relapsed/refractory acute myeloid leukemia (AML). BG1805 has already been studied in Investigator Initiated Studies, where it showed efficacy in both adults and children with blood malignancies and solid tumors. The BG1805 trial is the first of Bio-Gene’s CAR-T candidates to start formal clinical studies, although several have been tested in Investigator Initiated Trials. More details....
Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital